Steven Cohen Crinetics Pharmaceuticals, Inc. Transaction History
Point72 Asset Management, L.P.
- $44.6 Billion
- Q2 2025
A detailed history of Steven Cohen (Point72 Asset Management, L.P.) transactions in Crinetics Pharmaceuticals, Inc. stock. As of the latest transaction made, Point72 Asset Management, L.P. holds 1,998,161 shares of CRNX stock, worth $56.9 Million. This represents 0.13% of its overall portfolio holdings.
Number of Shares
1,998,161
Previous 778,398
156.7%
Holding current value
$56.9 Million
Previous $26.1 Million
120.12%
% of portfolio
0.13%
Previous 0.07%
Shares
23 transactions
Others Institutions Holding CRNX
# of Institutions
232Shares Held
90MCall Options Held
59.7KPut Options Held
14.8K-
Vanguard Group Inc Valley Forge, PA9.26MShares$264 Million0.0% of portfolio
-
Driehaus Capital Management LLC Chicago, IL6.4MShares$182 Million1.78% of portfolio
-
Black Rock Inc. New York, NY6.23MShares$177 Million0.01% of portfolio
-
Wellington Management Group LLP Boston, MA5.81MShares$165 Million0.03% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD5.59MShares$159 Million0.02% of portfolio
About Crinetics Pharmaceuticals, Inc.
- Ticker CRNX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 53,752,800
- Market Cap $1.53B
- Description
- Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III ...